First experience with intra-renal fenoldopam in a patient with heart failure

Journal of Invasive Cardiology

Volumn 17, Issue 5, 2005, Pages 274-276

  Cohen, Mauricio G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARVEDILOL; ENALAPRIL; FENOLDOPAM; MIDODRINE; SIMVASTATIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; CATHETER; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG INFUSION; HEART CATHETERIZATION; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; MALE;

AGED; CATHETERIZATION; ELECTROCARDIOGRAPHY; EQUIPMENT DESIGN; EQUIPMENT SAFETY; FENOLDOPAM; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEART FAILURE, CONGESTIVE; HUMANS; INFUSIONS, INTRA-ARTERIAL; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; RENAL ARTERY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 18244366851     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. U.S. Renal Data System, Chapter Nine: Cardiovascular Special Studies. In: USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda. MD: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases; 2001:148-158.
2. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-141.
3. Mathur VS, Teirstein P, Parel S, et al. Evidence for reduced systemic exposure to fenoldopam following local renal delivery compared to intravenous delivery. Blood Purif 2004;22:245(Abstract).
4. Mathur VS, Goodson B, Patel S, et al. Evidence for substantial renal first pass effects of human B-type natriuretic peptide (nesiritide) following intra-renal infusion. J Card Fail 2004;10:S68(Abstract).
5. Mathur VS, Teirstein T, Anderson E, et al. Targeted renal drug delivery with fenoldopam: A multicenter, randomized, controlled trial. J Am Soc Nephrol 2004;15:346A.
6. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA 2003;290:2284-2291.
7. Briguori C, Colombo A, Airoldi F, et al. N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004;44;762-765.
8. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy. Am Heart J 2002;143:894-903.
9. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-253.
10. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998;274:F63-F72.
11. La Villa G, Fronzaroli C, Lazzeri C et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J Clin Endocrinol Metab 1994;78:1166-1171.
12. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004;110:1620-1625.